Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis

Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles in asthma and PAR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of allergy, asthma, & immunology asthma, & immunology, 2020-11, Vol.125 (5), p.565-576.e1
Hauptverfasser:	Busse, William W., Maspero, Jorge F., Lu, Yufang, Corren, Jonathan, Hanania, Nicola A., Chipps, Bradley E., Katelaris, Constance H., FitzGerald, J. Mark, Quirce, Santiago, Ford, Linda B., Rice, Megan S., Kamat, Siddhesh, Khan, Asif H., Jagerschmidt, Alexandre, Harel, Sivan, Rowe, Paul, Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Graham, Neil M.H., Teper, Ariel
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-Allergic Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Asthma - drug therapy Biomarkers Double-Blind Method Eosinophils - cytology Female Forced Expiratory Volume - drug effects Humans Immunoglobulin E - blood Male Middle Aged Quality of Life Receptors, Interleukin-4, Type II - antagonists & inhibitors Rhinitis, Allergic, Perennial - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!